omniture
Telix Pharma

Latest News

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:50 2818

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:35 4287

Telix Refinances Convertible Bonds

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals L...

2026-04-14 16:32 4918

Telix and Regeneron Announce Strategic Radiopharma Collaboration

* Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical ther...

2026-04-13 06:57 3998

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-10 06:50 5104

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-09 06:58 4027

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-07 06:57 5971

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-02 06:59 4848

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-03-16 05:26 4772

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

* Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March ...

2026-03-10 06:34 4651

Investor Education Webinar

The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, Mar...

2026-03-02 06:56 3837

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-20 07:27 12863

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-18 05:54 7624

Telix Full Year Results 2025 Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2026-02-04 05:38 8255

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ...

2026-01-29 07:43 7529

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Li...

2026-01-20 15:16 10020

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-20 06:15 5564

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-17 03:21 4792

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2026-01-08 19:00 13763

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-12-22 05:40 4665
12345 ... 10